Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Brad Smith
AddedMar 31, 2024
UpdatedMay 31, 2026
Brad Smith

Brad Smith

Board Member, Lyra Therapeutics

LinkedIn

Brad Smith's Career

Lyra Therapeutics
Lyra Therapeutics

Watertown, MA, US

Board Member· Board
eGenesis
eGenesis

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Brad Smith's Career

Lyra Therapeutics
Lyra Therapeutics
Public$264.1M662014Watertown, MA, US
Board Member· Board

Leadership at Lyra Therapeutics

George WhitesidesGeorge WhitesidesCo-Founder
Nancy SnydermanNancy SnydermanBoard Member
Paulina HillPaulina HillBoard Member
Bob LangerBob LangerBoard Member
Maria BerkmanMaria BerkmanBoard Member
Konstantin PoukalovKonstantin PoukalovBoard Member

Similar to Lyra Therapeutics

LyndraLyndraWatertown, MA, USPharmaceuticals, Therapiesest. 2015LyndraWatertown, MA, US · est. 2015

US-based Lyndra Therapeutics develops therapies for Alzheimer's, HIV, opioid use disorder, and schizophrenia.

Series E · $284.6M161
Lyric PharmaceuticalsLyric PharmaceuticalsSan Francisco, CA, USTherapeuticsest. 2013Lyric PharmaceuticalsSan Francisco, CA, US · est. 2013

Lyric, a clinical-stage company, innovates gastrointestinal therapeutics for unmet hospital needs.

Series A · $20.4M6
Cara TherapeuticsCara TherapeuticsStamford, CT, USDrugs, Therapeuticsest. 2004Cara TherapeuticsStamford, CT, US · est. 2004

Cara Therapeutics, a Connecticut-based medical firm, develops novel drugs for pain and inflammation treatment.

Public · $517.2M106
Cyrano TherapeuticsCyrano TherapeuticsDelray Beach, FL, USPharmaceuticals, Therapeuticsest. 2014Cyrano TherapeuticsDelray Beach, FL, US · est. 2014

Cyrano Therapeutics: Innovating intranasal solutions to restore taste and smell functions.

Series B · $21.8M7
eGenesis
eGenesis
Series C$265M1052015Cambridge, MA, US
Board Member· Board

Leadership at eGenesis

Isaac CiechanoverIsaac CiechanoverBoard Member
Bob MoreBob MoreBoard Member
Al WiegmanAl WiegmanBoard Member
Boris NikolicBoris NikolicBoard Member
Mike CurtisMike CurtisCEO
Daniel LynchDaniel LynchBoard Member

Similar to eGenesis

Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
InGeneronInGeneronHouston, TX, USRegenerative Therapiesest. 2006InGeneronHouston, TX, US · est. 2006

InGeneron: A multinational biotech firm unlocking patient healing through innovative regenerative therapies.

Series D · $51M32
ExogenesisExogenesisBillerica, MA, USMedical Devicesest. 2005ExogenesisBillerica, MA, US · est. 2005

Exogenesis Corp., based in Billerica, US, develops and processes implantable medical devices.

Seed · $7.8M17
InscriptaInscriptaBoulder, CO, USGenome Engineeringest. 2015InscriptaBoulder, CO, US · est. 2015

Inscripta: Pioneering scalable digital genome engineering with an advanced, fully automated CRISPR-based platform.

Series A · $463.9M178

Brad Smith's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Brad Smith

Ryan ChenRyan ChenCo-Founder · NeuroAndrew ThompsonAndrew ThompsonCo-Founder · Spring Ridge VenturesGary EllisGary EllisBoard Member · ToroBrad HayesBrad HayesBoard Member · Builders FirstSourcePhilip RicePhilip RiceBoard Member · CoherixNancy KatzNancy KatzBoard Member · NeuroMetrix